secwatch.observer — SEC 8-K summary
======================================

Issuer:     FOXO TECHNOLOGIES INC. (FOXO)
CIK:        0001812360
Form:       8-K
Filed at:   2026-07-27T20:05:22+00:00
Accession:  0001493152-26-034793
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FOXO Tech unit Vector BioSource to buy 4 blood centers from Grifols for $3.5M plus earn-out
--------------------------------------------------------------------------------

- Vector BioSource, a FOXO subsidiary, agreed to buy four blood collection centers from Grifols Bio Supplies for $3.5M cash at closing.
- Earn-out of up to $1M payable if acquired business generates EBITDA of $1.5M or more in any calendar year 2026-2028.
- Closing conditioned on Vector obtaining new FDA license, CLIA certification, and waste-management permit independent of seller.
- Closing expected in Q3 or Q4 2026; long stop date is nine months from July 22, 2026.
- Acquired assets include serum inventory and existing cell units at the four collection centers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812360/000149315226034793/0001493152-26-034793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812360/000149315226034793/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-034793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer